Our Impact

A potent and selective degrader of the transcription factor STAT3 offers a new approach to a previously “undruggable” target. In a mouse model of leukemia, the degrader eliminated all of the tumors, with the mice remaining tumor-free for 60 days. In two mouse models of lymphoma, the drug eliminated all of the tumors for more than 100 days.

New research published in Nature Immunology shows that a combination of two immune-system factors could open up new avenues for treating Type 1 and Type 2 diabetes and obesity.

In a new study involving mouse models and prostate cancer cell lines, University of Michigan (U-M) researchers have demonstrated the preliminary effectiveness of a new set of compounds that offer a potential advance in the treatment of metastatic castration-resistant prostate cancer — one that appears to avoid many of the usual mechanisms of treatment resistance.

Groundbreaking new research involving mouse models marries high-intensity focused ultrasound with genetically modified cells, which may spur bone and soft tissue regeneration.

Recent research from Michigan Medicine scientists may help solve the mystery of how to detect and deal with higher-than-usual blood clot risk in patients who have experienced unprovoked venous thromboembolism. The study, done in mice and published in the Journal of Clinical Investigation, explores the role of inflammation in the development of deep vein thrombosis.

Using a new approach that combines data from human tumors grown in mice with data from The Cancer Genome Atlas, a team led by University of Michigan Rogel Cancer Center researchers has uncovered several previously unknown biomarkers for glioblastoma, the most common malignant brain tumor.

“Many patients are frustrated that they’ve had to try multiple therapies and still nothing is working well,” Allison Billi, M.D., Ph.D., says. “To be able to tell them that we’re working on a mouse that has the same disease as them, and that we need their help, brings out their motivation and interest in research.”

U-M researchers have discovered that the enzyme CPS1 can spur the body to prevent or repair acute liver injury in mice, which could be harnessed as a therapy or used as a biomarker to treat patients with liver damage.

A new multi-year, multi-disciplinary study examining Antiphospholipid Syndrome (APS) at the cellular level has found that two drugs reduced the development of blood clots in mice affected with the condition.

In a surprising finding, researchers from the University of Michigan Rogel Cancer Center have shown that knocking out NLRP6, a protein that plays a protective role in other diseases, led to better outcomes and less-severe symptoms after bone marrow transplants in mice.